April 2019 Vol 5 No 2
Anal CancerPatient StoriesHumor & CancerHPV Infection & Cancer
By Page Leggett
When Page Leggett found out that HPV infection, a common sexually transmitted disease, had caused her anal cancer, she relied on her incredible sense of humor to get through that experience and start a conversation about this taboo topic.
Adam Balinsky, President of Fifth Season Financial, discusses the company’s Funds for Living and Giving program, which provides financial help for people with advanced cancer by leveraging their existing life insurance policy.
Infusion of Hope
Tom Galioto, a volunteer at his local Tri-Cities Cancer Center in Kennewick, Washington, has always recognized the importance of maintaining a positive outlook and a sense of humor even in the face of a cancer diagnosis. He shares some of his favorite “inspirology” sayings, offering guidance and levity in making your challenges a little lighter.
From Your Navigator
Longtime nurse navigator Sharon Gentry describes how a nurse navigator will help ensure you get the best possible care during your treatment and beyond. The article includes useful sources and a handy chart for easy reference.
Clinical TrialsPatient StoriesSkin Cancer
After a lifetime of treating patients, Dr. David Crouch understood his own illness left little room for optimism as skin cancer returned again and again. As a last resort, he joined a clinical trial of a new immunotherapy that provided him a new lease on life. Today, after 2 years in remission, his mission is to educate people about this cancer and this immunotherapy.
Cancer ScreeningLung Cancer
By Dan Dean
“Lung cancer”—what first pops into your head when you hear that?
By Dana Taylor
Results of a recent study showed that using the targeted therapy Imbruvica (ibrutinib) as the first treatment in older adults with CLL was better than the combination of chemotherapy plus immunotherapy in slowing the progression of the disease.
FDA Approvals, News & UpdatesGastric Cancer
In February 2019, the FDA approved Lonsurf for the treatment of patients with metastatic gastric (stomach) cancer or gastroesophageal junction adenocarcinoma. This drug was previously approved only for patients with metastatic colorectal cancer.
Page 1 of 2
Results 1 - 10 of 19
Results 1 - 10 of 19